ReviewHaematologica2014
Management of chronic lymphocytic leukemia.
Review in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.JCO oncology practice · 2025Article
- Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.Journal of managed care & specialty pharmacy · 2024Article
- Article
- The Role ofCancers · 2020Review
- Methylation Data Processing Protocol and Comparison of Blood and Cerebral Spinal Fluid Following Aneurysmal Subarachnoid Hemorrhage.Frontiers in genetics · 2020Article
- Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia.Haematologica · 2019Article
- NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia.Oncology letters · 2019Article
- Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study.Cancer management and research · 2019Article
- Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter.Integrative medicine (Encinitas, Calif.) · 2018Article
- Article
- Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review.Drug safety - case reports · 2017Article
- Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.Nature communications · 2017Article
- Reactivating nuclear PTEN to treat CLL.Oncotarget · 2017Article
- The clinical implications of gene mutations in chronic lymphocytic leukaemia.British journal of cancer · 2016Review
- Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.Journal of hematology & oncology · 2016Article
- Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.Mediterranean journal of hematology and infectious diseases · 2016Review
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Journal of hematology & oncology · 2015Review
- CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.Human gene therapy · 2015Review
- Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.Molecular cancer · 2015Article
- DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.Frontiers in genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, the management of chronic lymphocytic leukemia has undergone profound changes that have been driven by an improved understanding of the biology of the disease and the approval of several new drugs. Moreover, many novel drugs are currently under evaluation for rapid approval or have been approved by regulatory agencies, further broadening the available therapeutic armamentarium for patients with chronic lymphocytic leukemia. The use of novel biological and genetic parameters combined with a careful clinical evaluation allows us to dissect some of the heterogeneity of the disease and to distinguish patients with a very mild onset and course, who often will not need any treatment, from those with an intermediate prognosis and a third group with a very aggressive course (high-risk leukemia). On this background, it becomes increasingly challenging to select the right treatment strategy. In this paper, we describe our own approach to the management of different patients with chronic lymphocytic leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.